Equities

Hemogenyx Pharmaceuticals PLC

Hemogenyx Pharmaceuticals PLC

Actions
Health CarePharmaceuticals and Biotechnology
  • Price (GBX)1.51
  • Today's Change-0.006 / -0.40%
  • Shares traded2.03m
  • 1 Year change+9.75%
  • Beta4.0128
Data delayed at least 20 minutes, as of Jun 07 2024 15:54 BST.
More ▼
Improved Notifications for Markets Data Alerts
Improved Notifications for Markets Data Alerts
Want push notifications sent directly to your devices for equity price changes and breaking news stories? Let us know here.
 
Existing alertsView our existing alerts
Find More Stocks
Find More Stocks
Use our equities screener to discover other potential opportunities.
 
Equities ScreenerGo to the Equities Screener

Profile data is unavailable for this security.

About the company

Hemogenyx Pharmaceuticals plc is a preclinical-stage biotechnology company. The Company is focused on the discovery, development and commercialization of treatments relating to bone marrow/hematopoietic (blood-forming) stem cell (BM/HSC) transplants for blood diseases, including leukemia, lymphoma and bone marrow failure and viral infections. It is developing several distinct and complementary product candidates, as well as a platform technology. To obviate the use of chemotherapeutic agents for conditioning of patients undergoing BM/HSC transplantations, the Company developed a method of selective elimination of hematopoietic stem cells/hematopoietic progenitors (HSC/HP) in patients using highly specific CDX antibodies. It has developed postnatal human hemogenic endothelial cells (Hu-PHEC cells) to generate cancer-free hematopoietic stem cells (HSC) for use in transplants to treat blood cancers. It has developed HEMO-CAR-T, for the potential treatment of acute myeloid leukemia (AML).

  • Revenue in GBP (TTM)0.00
  • Net income in GBP-6.69m
  • Incorporated2013
  • Employees17.00
  • Location
    Hemogenyx Pharmaceuticals PLC6th Floor, 60 Gracechurch StreetLONDON EC3V 0HRUnited KingdomGBR
  • Websitehttps://hemogenyx.com/
More ▼

Peer analysis

Key Information
CompanyRevenue (TTM)Net income (TTM)Market capEmployeesPrice/earnings (TTM)Price/book value (MRQ)Price/cash flow (TTM)Price/sales (TTM)EPS (excl. extraordinary items, TTM)EPS (incl. extraordinary items, TTM)Revenue per share (TTM)Book value per share (MRQ)Asset turnover (TTM)Inventory turnover (TTM)Receivables turnover (TTM)Revenues per employee (TTM)Return on avg assets (TTM)Return on avg assets (5 yr avg)Return on investment (TTM)Return on investment (5 yr avg)Gross margin (TTM)Gross margin
(5 yr avg)
Net profit margin (TTM)Net Profit margin
(5 yr avg)
Quick ratio (MRQ)Interest coverage (TTM)Total debt to capital (MRQ)Payout ratio
(5 yr avg)
Revenue
(YOY change %)
Revenue
(5 yr growth rate)
Net income
(YOY change %)
Net income
(5 yr growth rate)
Capital expenditure
(5 yr growth rate)
Dividend
(5 yr growth rate)
Genflow Biosciences PLC0.00-1.63m11.54m5.00--13.30-----0.0056-0.00560.000.00250.00----0.00-88.30---105.34--------------0.00-------21.97------
Proteome Sciences plc5.03m-2.44m11.81m35.00------2.35-0.0083-0.00830.017-0.01040.42093.893.04143,657.10-20.45-1.22----32.7654.53-48.59-2.200.2667-2.031.29---35.3710.52-284.38--126.22--
Oncimmune Holdings PLC1.21m-3.19m13.23m56.00------10.90-0.04270.09390.0163-0.01720.17561.190.6917---46.21------63.34---263.10--1.01-0.68151.32--------------
Synairgen plc0.00-9.99m13.57m30.00--0.8502-----0.0496-0.04960.000.07930.00----0.00-41.40-54.75-48.86-60.72-------83,247.62----0.00------63.74--0.00--
Provexis plc598.08k-496.59k13.58m2.00--13.54--22.70-0.0002-0.00020.00030.00040.67173.042.95299,040.00-55.78-48.82-41.86-33.6846.7286.14-83.03-97.641.96--0.00---8.5110.58-71.79------
Genincode PLC1.72m-6.73m13.71m28.00--1.56--7.99-0.0703-0.07030.01790.04970.16816.362.8861,285.71-65.92---72.37--47.55---392.31--5.85--0.0632--23.92---34.21------
Abingdon Health PLC5.34m-2.24m14.19m82.00--7.52--2.66-0.0184-0.01840.04390.01490.89787.674.7465,170.73-37.55-51.31-58.04-79.8557.3533.16-41.82-139.641.59--0.3572--42.68--83.77------
LungLife AI Inc36.04k-4.24m14.76m15.00--0.7423--409.62-0.1664-0.16640.00140.24330.0038--0.28312,402.76-44.11---50.09--100.00---11,767.39------0.0419--91.67--28.83------
Shield Therapeutics PLC13.09m-33.29m14.86m73.00--0.9884--1.14-0.0458-0.04580.01810.01920.3473.651.31179,246.60-88.29-56.68-136.30-67.4430.7852.20-254.44-365.892.04-30.010.5739--137.951.9533.13---2.50--
Destiny Pharma PLC0.00-5.66m15.04m19.00--1.63-----0.0624-0.06240.000.09650.00----0.00-60.33-54.32-67.28-59.97------------0.00------13.02--35.39--
OptiBiotix Health PLC689.10k-13.17m17.14m3.00--1.70--24.87-0.1489-0.14890.00780.10290.04262.281.25229,700.00-81.3517.83-83.4318.6649.3154.87-1,911.88190.543.24-0.0890.00---79.3519.05-58.686.2830.03--
Verici DX PLC793.70k-6.84m18.86m14.00--4.75--23.76-0.0402-0.04020.00470.01640.0932--1.5956,692.55-80.32---115.94--1.58---862.19------0.0438------23.43------
Hemogenyx Pharmaceuticals PLC0.00-6.69m19.66m17.00--6.11-----0.0061-0.00610.000.00240.00----0.00-101.47-82.19-112.85-95.97-----------28.030.5144-------68.14--36.68--
Skinbiotherapeutics PLC161.65k-2.88m19.97m11.00--5.15--123.56-0.0165-0.01650.00090.01920.05220.88710.418114,695.45-93.07-52.07-115.26-57.3362.90---1,784.70-4,694.376.48-379.780.0259--76.65---1.52--18.00--
Incanthera PLC0.00-1.48m20.35m8.00---------0.0192-0.01920.00-0.00860.00----0.00-373.20-101.74---132.88---------------------36.11------
Oxford Biodynamics PLC510.00k-10.83m27.10m45.00--2.90--53.14-0.0729-0.07290.00350.02990.03710.79870.33211,333.33-78.82-39.72-105.32-45.5252.16---2,122.75-1,324.621.72-7.500.5154--231.17-15.53-61.34---1.60--
Data as of Jun 07 2024. Currency figures normalised to Hemogenyx Pharmaceuticals PLC's reporting currency: UK Pound GBX
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.